A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease

New England Journal of Medicine

Volumn 327, Issue 18, 1992, Pages 1253-1259

  Davis, Kenneth L ^a   Thal, Leon J ^a   Gamzu, Elkan R ^a   Davis, Charles S ^a   Woolson, Robert F ^a   Gracon, Stephen I ^a   Drachman, David A ^a   Schneider, Lon S ^a   Whitehouse, Peter J ^a   Hoover, Toni M ^a   Morris, John C ^a   Kawas, Claudia H ^a   Knopman, David S ^a   Earl, Nancy L ^a   Kumar, Vinod ^a   Doody, Rachelle S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TACRINE;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0026756286     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199210293271801     Document Type: Article

References (23)

1. Sims NR, Bowen DM. Changes in choline acetyltransferase and in acetylcholine synthesis. In: Reisberg B, ed. Alzheimer's disease. New York: Free Press, 1983:88–92.
2. Drachman DA, Leavitt JB. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974; 30: 113–21.
3. Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139: 1421–4.
4. Thal LJ, Fuld PA, Masur DM, Sharpless NS. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 1983; 13: 491–6.
5. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142: 28–33.
6. Nielsen JA, Mena EE, Williams IH, Nocerini MR, Liston D. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol 1989; 173: 53–64.
7. Dawson RM. Tacrine slows the rate of aging of sarin-inhibited acetylcholinesterase. Neurosci Lett 1989; 100: 227–30.
8. Summers WK, Viesselman JO, Marsh GM, Candelora K. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry 1981; 16: 145–53.
9. Kaye WH, Sitaram H, Weingartner H, Ebert MH, Smallberg S, Gillin JC. Modest facilitation of memory in dementia with combined lecithin and anticholinesterase treatment. Biol Psychiatry 1982; 17: 275–80.
10. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241–5.
11. Division of Neuropharmacological Drug Products, Office of New Drug Evaluation (I), Center for Drug Evaluation and Review. An interim report from the FDA. N Engl J Med 1991; 324: 349–52.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939–44.
13. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98.
14. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486–8.
15. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356–64.
16. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988; 24: 458–62.
17. Clinical global impressions. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville, Md.: Department of Health, Education, and Welfare, 1976:218–22. (DHEW publication no. (ADM) 76–338.)
18. DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther 1989; 11: 545–54.
19. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 176–86.
20. Landis JR, Heyman ER, Koch GG. Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int Stat Rev 1978; 46: 237–54.
21. Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. BMJ 1990; 300: 495–9.
22. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine—lecithin combination treatment in patients with intermediate-stage Alzheimer's disease: results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 1990; 322: 1272–6.
23. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991; 337: 989–92.